Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02070744
Recruitment Status : Completed
First Posted : February 25, 2014
Results First Posted : April 13, 2018
Last Update Posted : April 13, 2018
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: VX-661 Drug: Ivacaftor Drug: Placebo matched to VX-661 Drug: Placebo matched to Ivacaftor Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 in Combination With Ivacaftor for 12 Weeks in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation With an Open-Label Extension
Study Start Date : March 2014
Actual Primary Completion Date : May 27, 2016
Actual Study Completion Date : May 27, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h
Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
Drug: VX-661
Tablet, oral use

Drug: Ivacaftor
Film coated tablet, oral use

Placebo Comparator: PC Phase: VX 661 placebo q12h + IVA placebo q12h
Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
Drug: Placebo matched to VX-661
Tablet, oral use

Drug: Placebo matched to Ivacaftor
Film coated tablet, oral use

Experimental: PC Phase: VX-661 100 mg qd + IVA 150 mg q12h
Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
Drug: VX-661
Tablet, oral use

Drug: Ivacaftor
Film coated tablet, oral use

Placebo Comparator: PC Phase: VX -661 placebo qd + IVA placebo q12h
Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
Drug: Placebo matched to VX-661
Tablet, oral use

Drug: Placebo matched to Ivacaftor
Film coated tablet, oral use

Experimental: OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h
Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
Drug: VX-661
Tablet, oral use

Drug: Ivacaftor
Film coated tablet, oral use




Primary Outcome Measures :
  1. PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline (PC Phase) up to 112 days ]
    AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.

  2. OLE Phase: Number of Participants With Treatment-Emergent AEs and SAEs [ Time Frame: Baseline (OLE Phase) up to 364 days ]
    AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.


Secondary Outcome Measures :
  1. PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12 [ Time Frame: Baseline (PC Phase), Through Week 12 ]
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.

  2. OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40 [ Time Frame: Baseline (OLE Phase), Through Week 40 ]
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.

  3. PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12 [ Time Frame: Baseline (PC Phase), Through Week 12 ]
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.

  4. OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40 [ Time Frame: Baseline (OLE Phase), Through Week 40 ]
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.

  5. PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12 [ Time Frame: Baseline (PC Phase), Through Week 12 ]
    Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.

  6. OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40 [ Time Frame: Baseline (OLE Phase), Through Week 40 ]
    Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.

  7. PC Phase: Absolute Change From Baseline in Body Weight at Week 12 [ Time Frame: Baseline (PC Phase), Week 12 ]
    Baseline was defined as Day 1 of PC Phase.

  8. OLE Phase: Absolute Change From Baseline in Body Weight at Week 40 [ Time Frame: Baseline (OLE Phase), Week 40 ]
    Baseline was defined as Day 1 of the OLE Phase.

  9. PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12 [ Time Frame: Baseline (PC Phase), Week 12 ]
    BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m^2). Baseline was defined as Day 1 of PC Phase.

  10. OLE Phase: Absolute Change From Baseline BMI at Week 40 [ Time Frame: Baseline (OLE Phase), Week 40 ]
    BMI was calculated using following formula: BMI = Weight in kg/height in m^2. Baseline was defined as Day 1 of the OLE Phase.

  11. PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12 [ Time Frame: Baseline (PC Phase), Through Week 12 ]
    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.

  12. OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40 [ Time Frame: Baseline (OLE Phase), Through Week 40 ]
    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.

  13. PC Phase: Maximum Plasma Concentration (Cmax) of VX-661 and IVA [ Time Frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85 ]
  14. PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 [ Time Frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85 ]
    Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.

  15. PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA [ Time Frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85 ]
  16. PC Phase: Time to Reach Cmax (Tmax) of VX-661 and IVA [ Time Frame: Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Homozygous for the F508del CFTR mutation
  • FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height
  • Stable CF disease as judged by the investigator

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
  • Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at screening and Day 1 of the PC Phase and Day -7 or Day 1 of the OLE Phase (whichever was applicable)
  • Sexually active participants of reproductive potential who are not willing to follow the contraception requirements
  • The participant or a close relative of the participant is the investigator or sub investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02070744


  Show 23 Study Locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated

Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT02070744     History of Changes
Other Study ID Numbers: VX13-661-103
First Posted: February 25, 2014    Key Record Dates
Results First Posted: April 13, 2018
Last Update Posted: April 13, 2018
Last Verified: March 2018

Keywords provided by Vertex Pharmaceuticals Incorporated:
CF

Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrosis
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Ivacaftor
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action